All In Biotech

Drug Trial Radar · NCT01248195

Optimization of Treatment and Management of Schizophrenia in Europe

Last checked: Nov 19, 2026Latest source record: May 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 479 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

479

Actual

Start

May 2011

Primary completion

Apr 2016

Study completion Apr 2016

Sponsor

Lead sponsor
Rene KahnAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
King's College London; Technical University of Munich; University of Manchester; Ludwig-Maximilians - University of Munich
First posted
Nov 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development.

Conditions

  • Schizophrenia
  • Schizophreniform Disorder
  • Schizoaffective Disorder

Interventions

  • Amisulpride open labelDrug

    4-week open label amisulpride treatment

  • 6-week amisulpride double blind treatmentDrug

    6-week amisulpride double blind treatment

  • 6-week olanzapine double blind treatmentDrug

    6-week olanzapine double blind treatment

  • 12-week clozapine open-label treatmentDrug

    12-week clozapine open-label treatment

  • Psychosocial interventionBehavioral

    Psychosocial intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PANSSTime frame: Jan 2016
  2. Sellwood rating scaleTime frame: Jan 2016
  3. Biological profileTime frame: jan 2016
  4. MRS measuresTime frame: jan 2016
  5. SOFAS global functioningTime frame: jan 2016
  6. MRI assessmentsTime frame: jan 2016

Locations

26 sites in 16 countries. Site status is shown where the registry gives one.

  • Melbourne Neuropsychiatry Centre

    Melbourne, Australia

  • Department of Biological Psychiatry, Innsbruck University Clinics

    Innsbruck, Austria

  • Katholieke Universiteit Leuven (KU Leuven)

    Leuven, Belgium

  • University Specialised Hospital for Active Treatment in Neurology and Psychiatry "St. Naum"

    Sofia, Bulgaria

  • Psychiatrická klinika LF UK, Fakultní nemocnice

    Hradec Králové, Czechia

  • Psychiatrické centrum Praha

    Prague, Ustavni 91, Czechia

  • Center for Neuropsychiatric Research

    Glostrup Municipality, Denmark

  • Institut National de la Santé et de la Reserche Médicale (INSERM)

    Créteil, France

  • Martin-Luther-University (MLU) of Halle-Wittenberg

    Halle, Germany

  • Deprtment of Psychiatry, University of Heidelberg

    Mannheim, Germany

  • Ludwig-Maximilians University München

    München, Germany

  • Technische Universität München (TUM)

    München, Germany

  • Sheba Medical Centre Department of Psychiatry

    Tel HaShomer, Israel

  • Department of Psychiatry University of Naples

    Naples, Italy

  • University Medical Center Utrecht

    Utrecht, Netherlands

  • Department of Adult Psychiatry, University of Medical Sciences

    Poznan, Poland

  • Obregia Psychiatric Hospital

    Bucharest, Romania

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Servicio Madrileño de Salud (SERMAS)

    Madrid, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Instituto de Investigación Hospital 12 de Octubre

    Madrid, Spain

  • Universidad de Oviedo

    Oviedo, Spain

  • Clienia Schlössli AG, Privatklinik für Psychiatrie und Psychotherapie

    Oetwil, Switzerland

  • King's College London, Departments of Psychological Medicine, Psychiatry & Cognitive Neuroscience

    London, United Kingdom

  • West London Mental Health Trust

    London, United Kingdom

  • University of Manchester

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.